Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 
Tunisia Protests Grow as Opposition Unites Against President Kais Saied’s Rule 
Lab-grown meat: you may find it icky, but it could drive forward medical research 
Brazil Arrests Former Peruvian Foreign Minister Augusto Blacker Miller in International Fraud Case 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Tabletop particle accelerator could transform medicine and materials science 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation 
U.S. Stock Futures Edge Higher as Micron Earnings Boost AI Sentiment Ahead of CPI Data 
U.S. Lifts Sanctions on Brazilian Supreme Court Justice Amid Shift in Brazil Relations 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
California, 18 States Sue to Block Trump’s $100,000 H-1B Visa Fee 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
